Summit Therapeutics IncNASDAQ SMMT Stock Report

Summit Therapeutics, Inc. a biopharmaceutical company, which discovers, develops, and commercializes medicines to treat infectious diseases. The company is headquartered in Menlo Park, California. The company went IPO on 2004-10-14. The firm is focused on discovering, developing, and commercializing antibiotics for serious infectious diseases. Its lead CDI product candidate is ridinilazole is an orally administered small molecule antibiotic. The firm's preclinical candidates include SMT-738, from the DDS-04 series for development in the fight against multidrug-resistant infections, specifically carbapenem-resistant Enterobacteriaceae (CRE) infections. The firm is conducting a Phase III clinical program, which is focused on treating patients suffering from Clostridioides difficile infection, also known as C. difficile infection (CDI). The firm is also seeking to expand its product candidate portfolio through the development of a new mechanism, precision antibiotics using its Discuva Platform.